Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

New molecular and immunotherapeutic approaches in biliary cancer.

Goldstein D, Lemech C, Valle J.

ESMO Open. 2017 Mar 27;2(Suppl 1):e000152. doi: 10.1136/esmoopen-2016-000152. eCollection 2017. Review.

2.

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.

Mateo J, Ganji G, Lemech C, Burris HA, Han SW, Swales K, Decordova S, DeYoung MP, Smith DA, Kalyana-Sundaram S, Wu J, Motwani M, Kumar R, Tolson JM, Rha SY, Chung HC, Eder JP, Sharma S, Bang YJ, Infante JR, Yan L, de Bono JS, Arkenau HT.

Clin Cancer Res. 2017 Oct 1;23(19):5981-5992. doi: 10.1158/1078-0432.CCR-17-0725. Epub 2017 Jun 23.

PMID:
28645941
3.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TR, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean E, Brown J, Gibson D, Peddareddigari V, Murray S, Nebot N, Mazumdar J, Swartz L, Auger KR, Fleming RA, Singh R, Millward M.

Ann Oncol. 2016 Dec;27(12):2268-2274. doi: 10.1093/annonc/mdw427. Epub 2016 Oct 11.

PMID:
27733373
4.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG.

Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.

5.

Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report.

Lemech CR, Williams R, Thompson SR, McCaughan B, Chin M.

BMC Res Notes. 2016 Aug 3;9:386. doi: 10.1186/s13104-016-2189-x.

6.

Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT.

Hughes A, Landers D, Arkenau HT, Shah S, Stephens R, Mahal A, Simmons M, Lemech C, Royle J.

Adv Ther. 2016 Sep;33(9):1677-1678. No abstract available.

7.

Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.

Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N, Olaitan A, Mould T, Meyer T, Hartley J, Mitra A, Ledermann JA, McCormack M, Kristeleit RS.

Oncology. 2016;91(1):48-54. doi: 10.1159/000445999. Epub 2016 Jun 3.

PMID:
27256106
8.

Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT.

Hughes A, Landers D, Arkenau HT, Shah S, Stephens R, Mahal A, Simmons M, Lemech C, Royle J.

Adv Ther. 2016 Jun;33(6):1012-24. doi: 10.1007/s12325-016-0335-4. Epub 2016 May 11. Erratum in: Adv Ther. 2016 Sep;33(9):1677-8.

9.

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.

Bendell JC, Patel MR, Yoshida K, Seraj J, Weaver R, Lemech C, Todaro TG, Pant S, Arkenau HT.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1275-83. doi: 10.1007/s00280-016-3031-9. Epub 2016 May 5.

10.

Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.

Laille E, Patel M, Jones SF, Burris HA 3rd, Infante J, Lemech C, Liu L, Arkenau HT.

J Clin Pharmacol. 2015 Dec;55(12):1378-85. doi: 10.1002/jcph.560. Epub 2015 Jul 29.

11.

Patients' perceptions of research biopsies in phase I oncology trials.

Lemech C, Dua D, Newmark J, Saggese M, Simmons E, Spiliopoulou P, Arkenau HT.

Oncology. 2015;88(2):95-102. doi: 10.1159/000368161. Epub 2014 Oct 14.

PMID:
25322682
12.

Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers.

Hillman RJ, Garland SM, Gunathilake MP, Stevens M, Kumaradevan N, Lemech C, Ward RL, Meagher A, McHugh L, Jin F, Carroll S, Goldstein D, Grulich AE, Tabrizi SN.

Int J Cancer. 2014 Aug 15;135(4):996-1001. doi: 10.1002/ijc.28730. Epub 2014 Feb 4.

13.

Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development.

Jones A, Teschendorff AE, Li Q, Hayward JD, Kannan A, Mould T, West J, Zikan M, Cibula D, Fiegl H, Lee SH, Wik E, Hadwin R, Arora R, Lemech C, Turunen H, Pakarinen P, Jacobs IJ, Salvesen HB, Bagchi MK, Bagchi IC, Widschwendter M.

PLoS Med. 2013 Nov;10(11):e1001551. doi: 10.1371/journal.pmed.1001551. Epub 2013 Nov 12.

14.

The future is here: tumour profiling in day-to-day clinical practice.

Lemech CR, Arkenau HT.

Drug Discov Today. 2013 Aug;18(15-16):689-91. doi: 10.1016/j.drudis.2013.06.006. Epub 2013 Jun 22. No abstract available.

PMID:
23796913
15.

Combination molecularly targeted drug therapy in metastatic melanoma: progress to date.

Lemech C, Infante J, Arkenau HT.

Drugs. 2013 Jun;73(8):767-77. doi: 10.1007/s40265-013-0049-8.

PMID:
23649971
16.

Research biopsies in the context of early phase oncology studies: clinical and ethical considerations.

Saggese M, Dua D, Simmons E, Lemech C, Arkenau HT.

Oncol Rev. 2013 Aug 30;7(1):e5. doi: 10.4081/oncol.2013.e5. eCollection 2013 Apr 22. Review.

17.

Advanced gastric cancer: is there enough evidence to call second-line therapy standard?

Arkenau HT, Saggese M, Lemech C.

World J Gastroenterol. 2012 Nov 28;18(44):6376-8. doi: 10.3748/wjg.v18.i44.6376.

18.

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence.

Lemech C, Infante J, Arkenau HT.

Ther Adv Med Oncol. 2012 Mar;4(2):61-73. doi: 10.1177/1758834011432949.

19.

Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities.

Lemech C, Arkenau HT.

Clin Med Insights Oncol. 2012;6:53-66. doi: 10.4137/CMO.S5855. Epub 2012 Jan 5.

20.

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.

Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD.

Clin Cancer Res. 2011 Apr 15;17(8):2538-48. doi: 10.1158/1078-0432.CCR-10-3314. Epub 2011 Feb 22.

21.

Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice.

Lemech C, Arkenau HT.

Cancers (Basel). 2011 Apr 1;3(2):1844-60. doi: 10.3390/cancers3021844.

Supplemental Content

Loading ...
Support Center